Deal-Making

Novartis licenses Factor XI Ab to Blackstone-backed $250m bio firm

Newly launched firm Anthos Therapeutics has licensed Novartis candidate MAA868 and will look to develop it for cardiovascular disorders. Novartis retains a minority stake in the Blackstone-backed biopharma. Private investment firm Blackstone Life Sciences launched this week Anthos Therapeutics, a biopharma company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. The company, backed by $250 million (‚ā¨220 million) of Blackstone funds, will look to a Novartis candidate as a potential anti-thrombotic therapy to treat patients currently underserved by…

Hey Big Vendor: With GE, Danaher becomes largest bioprocess player

The $21.4 billion addition of GE Healthcare‚Äôs Biopharma business will complement Pall‚Äôs technologies to bring biomanufacturers a fully end-to-end bioprocessing offering. BioProcess Insider reported the news that Danaher Corporation has agreed to buy the Biopharma division of GE Healthcare‚Äôs Life Sciences business for approximately $21.4 billion (‚ā¨18.9 billion) on Monday. If the deal is completed, it will be the biggest merger in the bioprocessing space, dwarfing Danaher‚Äôs previous $13.8 billion takeover of Pall Corporation in 2015, and the similar size…

Danaher absorbing GE’s bioprocess biz in $21.4bn deal

Danaher Corporation will consolidate its position in the supplier space through the $21.4 billion acquisition of GE Healthcare‚Äôs biopharma division. The business will not be integrated with Pall. The deal, expected to be completed in the fourth quarter of 2019, will see Danaher Corporation buy the full BioPharma portion of GE Healthcare‚Äôs Life Sciences business for a cash purchase price of approximately $21.4 billion (‚ā¨18.9 billion). The business, which pulls in about $3 billion in annual revenue, provides tools to…

Roche to buy gene therapy firm Spark for $4.3bn

The acquisition of Spark Therapeutics will add commercial product Luxturna to Roche‚Äôs portfolio, along with a pipeline of gene therapies. Swiss pharma firm Roche has announced today it is set to buy Spark Therapeutics for approximately $4.3 billion (‚ā¨3.8 billion). ‚ÄúThe merger agreement has been unanimously approved by the boards of Spark Therapeutics and Roche,‚ÄĚ Roche spokesperson Simone Oeschger told BioProcess Insider. ‚ÄúUnder the terms of the merger agreement, Roche will promptly commence a tender offer, to acquire all outstanding…

Merck accessing cancer vaccine tech through $300m acquisition

Merck & Co. will acquire Immune Design for $300 million, adding cancer immunization and adjuvant systems technologies to its portfolio. The deal, expected to close early in the second quarter of 2019, sees Merck & Co. (known as MSD outside of North America) acquire late-stage Californian immunotherapy firm Immune Design for $5.85 (‚ā¨5.15) per share in cash, totaling around $300 million. ‚ÄúOur primary interest to acquire Immune Design is related to their unique portfolio of approaches to cancer immunization and…

From Sartorius to VC, Dynamk’s new MD talks life science investment

AI, regenerative medicine enabling technologies, and clinical diagnostics are major investment opportunities, says life science executive Reinhard Vogt who has joined Dynamk Capital. Reinhard Vogt served as an executive at Sartorius AG for over 35 years. During his tenure, he was responsible for the strategic development of the firm‚Äôs Bioprocess Division that grew from around $30 Million to around $1.2 billion today, reached through a combination of strong organic growth and a strong focus on M&A and the integration of…

AGC Bio ‘CHOsen’ to make Interleukin-15 inhibitor for Serono spin-off

CDMO AGC Biologics will develop the process and manufacture Calypso‚Äôs CALY-002, a humanized monoclonal antibody manufactured in a CHO cell line, from its site in Denmark. Calypso Biotech, a spin-off from Merck Serono, has selected contract development and manufacturing organization (CDMO) AGC Biologics for the process development and cGMP production of its lead candidate CALY-002. The work will be undertaken at AGC Bio‚Äôs site in Copenhagen, Denmark. Financials of the deal have not been divulged, but Calypso‚Äôs CEO Alain Vicari…

‚ÄėImpressive roster of participants‚Äô brings $42m to PureTech affiliate

Vor Biopharma, founded by PureTech, has raised $42 million to support its hematopoietic stem cell (HSC)-based candidate through Series A financing round. Vor Biopharma, co-founded by biopharma firm PureTech, will use the $42 million (‚ā¨37 million) to advance its lead HSC-based preclinical candidate for the treatment of acute myeloid leukemia (AML) and to further build its pipeline to treat hematologic malignancies. According to Jefferies equity analyst Peter Welford, the Series A financing round included an ‚Äúimpressive roster of participants,‚Äô led…

Big Pharma and CAR-T: Testing the water or in at the deep end?

Following Novartis and Gilead‚Äôs success, others are ‚Äúscrambling to build up their T-Cell capabilities,‚ÄĚ say venture capitalists. We look at where Big Pharma stands in this blossoming sector. Big Pharma firms will be looking at strategies to enter the chimeric antigen receptor (CAR) T-cell space, if they have not already, spurred on by the approvals in 2017 of¬†Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) . This was the view of commentators and analysts at Phacilitate in Miami, Florida last month. Anna…

Dual sourcing drives global network as WuXi inks Amicus deal

WuXi Biologics will harness its growing global network to supply the commercial drug substance and product for Amicus Therapeutics’ Pompe biologic ATB200. Amicus Therapeutics is developing a therapy consisting of recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure, administered with a small molecule pharmacological chaperone. The product, ATB200, will be made by contract development and manufacturing organization (CDMO) WuXi Biologics. The firm, which has been working with Amicus to scale-up the product over the past few years,…